Workshop on immunizations in older adults: Identifying future research agendas

Journal of the American Geriatrics Society

Volumn 58, Issue 4, 2010, Pages 765-776

  High, Kevin P ^a   D'Aquila, Richard T ^b   Fuldner, Rebecca A ^c   Gerding, Dale N ^d   Halter, Jeffrey B ^e   Haynes, Laura ^f   Hazzard, William R ^g   Jackson, Lisa A ^h   Janoff, Edward ⁱ   Levin, Myron J ⁱ   Nayfield, Susan G ^c   Nichol, Kristin L ^j   Prabhudas, Mercy ^k   Talbot, Helen K ^b   Clayton, Charles P ^l   Henderson, Randi ^l   Scott, Catherine M ^l   Tarver, Erika D ^l   Woolard, Nancy F ^a   Schmader, Kenneth E ^m  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d HINES VA HOSPITAL   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f TRUDEAU INSTITUTE   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h CENTER FOR HEALTH STUDIES   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^l Association of Specialty Professors   (Colombia)

^m DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Immunization; Vaccination

Indexed keywords

ADJUVANT; AGATOLIMOD; ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS B VACCINE; INFLUENZA VACCINE; ISCOM; LIPID EMULSION; MONOCLONAL ANTIBODY; PNEUMOCOCCUS VACCINE; SAPONIN; STAPHYLOCOCCUS VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG; V 710; VACCINE; VARICELLA ZOSTER VACCINE; VIRUS VACCINE;

AGE; AGED; AGING; CELL FUNCTION; CELLULAR IMMUNODEFICIENCY; CHRONIC DISEASE; CLINICAL TRIAL; DEATH; DENDRITIC CELL; DISEASE EXACERBATION; DRUG EFFICACY; FRAIL ELDERLY; FUNCTIONAL ASSESSMENT; HEALTH CARE ORGANIZATION; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; LYMPHOCYTE PROLIFERATION; MEDICAL RESEARCH; NONHUMAN; PNEUMOCOCCAL INFECTION; PROPHYLAXIS; REVIEW; RISK REDUCTION; T LYMPHOCYTE; WORKSHOP;

ADAPTIVE IMMUNITY; AGED; AGING; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); EVIDENCE-BASED PRACTICE; FORECASTING; GERIATRICS; HEALTH PLANNING GUIDELINES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNIZATION SCHEDULE; RESEARCH; T-LYMPHOCYTES; TELOMERE; UNITED STATES; VACCINATION;

EID: 77950412178     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02772.x     Document Type: Review

References (96)

1. World Population Prospects: The 2006 Revision and World Urbanization Prospects: The 2005 Revision, Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat [on-line]. Available at Accessed December 30, 2008.
2. High K. Immunizations in older adults. Clin Geriatr Med 2007 23:669 685. (Pubitemid 47042347)
3. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 289:179 186. (Pubitemid 36068705)
4. Vaccines and Immunizations. Centers for Disease Control and Prevention [on-line]. Available at Accessed May 15, 2009.
5. Poland GA, Schaffner W. Immunization guidelines for adult patients: An annual update and a challenge. Ann Intern Med 2009 150:53 54.
6. Nichol KL, Nordin JD, Nelson DB et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007 357:1373 1381. (Pubitemid 47535592)
7. Jackson ML, Nelson JC, Weiss NS et al. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: A population-based, nested case-control study. Lancet 2008 372:398 405.
8. Jackson LA, Jackson ML, Nelson JC et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006 35:337 344.
9. Falsey AR, Walsh EE, Francis CW et al. Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. J Infect Dis 2001 183:995 999.
10. Nichol KL, Nordin J, Mullooly J et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003 348:1322 1332. (Pubitemid 36384099)
11. Lamontagne F, Garant MP, Carvalho JC et al. Pneumococcal vaccination and risk of myocardial infarction. Can Med Assoc J 2008 179:773 777.
12. Ferrucci L, Guralnik JM, Pahor M et al. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA 1997 277:728 734. (Pubitemid 27106225)
13. Barker WH, Borisute H, Cox C. A study of the impact of influenza on the functional status of frail older people. Arch Intern Med 1998 158:645 650.
14. Falsey AR, Hennessey PA, Formica MA et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005 352:1749 1759. (Pubitemid 40570923)
15. High KP. Immunizations in older adults. Clin Geriatr Med 2007 3:669 685.
16. Weinberger B, Herndler-Brandstetter D, Schwanninger A et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008 46:1078 1084. (Pubitemid 351589876)
17. Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: Implications for vaccination in the elderly. Expert Rev Mol Med 2007 9:1 17. (Pubitemid 46322025)
18. Kovaiou RD, Grubeck-Loebenstein B. Age-associated changes within CD4+T cells. Immunol Lett 2006 107:8 14.
19. van Duin D, Mohanty S, Thomas V et al. Age-associated defect in human TLR-1/2 function. J Immunol 2007 178:970 975. (Pubitemid 46095170)
20. Stout-Delgado HW, Yang X, Walker WE et al. Aging impairs IFN regulatory factor 7 up-regulation in plasmacytoid dendritic cells during TLR9 activation. J Immunol 2008 181:6747 6756.
21. Takahashi K, Shibata T, Akashi-Takamura S et al. A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responses. J Exp Med 2007 204:2963 2976. (Pubitemid 350179564)
22. Haynes L, Swain SL. Why aging T cells fail: Implications for vaccination. Immunity 2006 24:663 666. (Pubitemid 43867372)
23. Haynes L, Eaton SM. The effect of age on the cognate function of CD4+T cells. Immunol Rev 2005 205:220 228. (Pubitemid 40780188)
24. Haynes L. How vaccines work on the background of the aging immune system. Exp Gerontol 2007 42:438 440. (Pubitemid 46561173)
25. Cicin-Sain L, Messaoudi I, Park B et al. Dramatic increase in naïve T cell turnover is linked to loss of naive T cells from old primates. Proc Natl Acad Sci U S A 2007 104:19960 19965.
26. Nikolich-Zugich J. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol 2008 8:512 522. (Pubitemid 351913675)
27. Carson PJ, Nichol KL, O'Brien J et al. Immune function and vaccine responses in healthy advanced elderly patients. Arch Intern Med 2000 160:2017 2024. (Pubitemid 30437585)
28. Goronzy JJ, Fulbright JW, Crowson CS et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001 75:12182 12187.
29. Hakim FT, Memon SA, Cepeda R et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 2005 115:930 939. (Pubitemid 40489397)
30. Naylor K, Li G, Vallejo AN et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005 174:7446 7452. (Pubitemid 40705717)
31. Lee WW, Cui D, Czesnikiewicz-Guzik M et al. Age-dependent signature of metallothionein expression in primary CD4 T cell responses is due to sustained zinc signaling. Rejuvenation Res 2008 11:1001 1011.
32. Czesnikiewicz-Guzik M, Lee WW, Cui D et al. T cell subset-specific susceptibility to aging. Clin Immunol 2008 127:107 118.
33. Clambey ET, White J, Kappler JW et al. Identification of two major types of age-associated CD8 clonal expansions with highly divergent properties. Proc Natl Acad Sci U S A 2008 105:12997 13002.
34. Paganelli R, Quinti I, Fagiolo U et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol 1992 90:351 354.
35. Sansoni P, Vescovini R, Fagnoni F et al. The immune system in extreme longevity. Exp Gerontol 2008 43:61 65.
36. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007 211:144 156.
37. Son NH, Murray S, Yanovski J et al. Lineage specific telomere shortening and unaltered capacity for telomerase expression in human T and By lymphocytes with age. J Immunol 2000 165:1191 1196. (Pubitemid 30604544)
38. Weng N-P. Telomere and the adaptive immunity. Mech Ageing Dev 2008 129:60 66.
39. Weng N-P. Aging of the immune system: How much can the adaptive immunity adapt? Immunity 2006 24:495 499.
40. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 289:179 186. (Pubitemid 36068705)
41. Jefferson TO, Rivetti D, Di Pietrantonj C et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; (2):CD001269.
42. Aspinall R, Del Giudice G, Effros RB et al. Challenges for vaccination in the elderly. Immun Ageing 2007 4:9. (Pubitemid 351248158)
43. Simonsen L, Reichert TA, Viboud C et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005 165:265 272. (Pubitemid 40216277)
44. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991 325:1453 1460.
45. Törling J, Hedlund J, Konradsen HB et al. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003 22:96 103. (Pubitemid 37357156)
46. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987 83:425 430.
47. Sims RV, Steinmann WC, McConville JH et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988 108:653 657.
48. Butler JC, Breiman RF, Campbell JF et al. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 1993 270:1826 1831.
49. Farr BM, Johnston BL, Cobb DK et al. Preventing pneumococcal bacteremia in patients at risk: Results of a matched case-control study. Arch Intern Med 1995 155:2336 2340.
50. Andrews RM, Counahan ML, Hogg GG et al. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine 2004 23:132 138.
51. Dominguez A, Salleras L, Fedson DS et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: A case-control study. Clin Infect Dis 2005 40:1250 1257. (Pubitemid 40570233)
52. de Roux A, Schmöle-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: Conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008 46:1015 1023. (Pubitemid 351589866)
53. Moberley SA, Holden J, Tatham DP et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;(1):CD000422.
54. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses. Eur J Epidemiol 2004 19:353 363. (Pubitemid 39005435)
55. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: New paradigms for protection. Clin Infect Dis 2008 47:1328 1338.
56. Hak E, Sanders EA, Verheij TJ et al. Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008 66:378 383.
57. Guris D, Jumaan AO, Mascola L et al. Changing varicella epidemiology in active surveillance sites - United States, 1995-2005. J Infect Dis 2008 197 (Suppl 2):S71 S75 CDC, unpublished data.
58. Levin MJ, Oxman MN, Zhang JH et al. Veterans affairs cooperative studies program shingles prevention study investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008 197:825 835.
59. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007 13:1417 1419. (Pubitemid 47510317)
60. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998 26:1027 1034.
61. Kyne L, Warny M, Qamar A et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001 357:189 193. (Pubitemid 32108091)
62. Aboudola S, Kotloff KL, Kyne L et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003 71:1608 1610. (Pubitemid 36254357)
63. Phares CR, Lynfield R, Farley MM et al. Active bacterial core surveillance/emerging infections program network. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008 299:2056 2065.
64. Baker CJ, Paoletti LC, Rench MA et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 2004 189:1103 1112.
65. Palazzi DL, Rench MA, Edwards MS et al. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis 2004 190:558 564.
66. Elixhauser A, Steiner C. Infections with Methicillin-Resistant Staphylococcus aureus (MRSA) in U.S. hospitals, 1993-2005 [on-line]. Available at Accessed November 10, 2009.
67. Furuya EY, Cook HA, Lee MH et al. Community-associated methicillin-resistant Staphylococcus aureus prevalence: How common is it? A methodological comparison of prevalence ascertainment. Am J Infect Control 2007 35:359 366.
68. Maira-Litrán T, Kropec A, Goldmann DA et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 2005 73:6752 6762. Erratum in: Infect Immun 2005;73:7789. (Pubitemid 41368842)
69. Kelly-Quintos C, Cavacini LA, Posner MR et al. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect Immun 2006 74:2742 2750. (Pubitemid 43672983)
70. Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: Iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006 74:2215 2223.
71. Schoenbaum SC, Mostow SR, Dowdle WR et al. Studies with inactivated influenza vaccines purified by zonal centrifugation: 2. Efficacy. Bull WHO 1969 41:531 535.
72. Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006 166:1121 1127.
73. Powers DC, Smith GE, Anderson EL et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995 171:1595 1599.
74. Lakey DL, Treanor JJ, Betts RF et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 1996 174:838 841.
75. Treanor JJ, Betts RF, Smith GE et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis 1996 173:1467 1470.
76. Treanor JJ, Schiff GM, Couch RB et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006 193:1223 1228.
77. Treanor JJ, Schiff GM, Hayden FG et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial. JAMA 2007 297:1577 1582.
78. Haynes L., Eaton SM. The effect of age on the cognate function of CD4+T cells. Immunol Rev 2005 205:220 228. (Pubitemid 40780188)
79. Eaton SM, Burns EM, Kusser K et al. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med 2004 200:1613 1622. (Pubitemid 40094185)
80. Haynes L, Eaton SM, Burns EM et al. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 2004 172:5194 5199. (Pubitemid 38542015)
81. Renshaw M, Rockwell J, Engleman C et al. Cutting edge: Impaired Toll-like receptor expression and function in aging. J Immunol 2002 169:4697 4701. (Pubitemid 35217128)
82. Sharma S, Dominguez AL, Hoelzinger DB et al. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: The implications for vaccinations in the aged. Cancer Immunol Immunother 2008 57:549 561. (Pubitemid 351170538)
83. Maletto BA, Rópolo AS, Liscovsky MV et al. CpG oligodeoxynucleotides functions as an effective adjuvant in aged BALB/c mice. Clin Immunol 2005 117:251 261.
84. Subramanian S, Divya Shree AN. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats. Neurosci Lett 2008 436:219 222.
85. Sen G, Chen Q, Snapper CM. Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels. Infect Immun 2006 74:2177 2186.
86. Manning BM, Enioutina EY, Visic DM et al. CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp Gerontol 2001 37:107 126.
87. Alignani D, Maletto B, Liscovsky M et al. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukoc Biol 2005 77:898 905. (Pubitemid 40770841)
88. Speiser DE, Liénard D, Rufer N et al. Rapid and strong human CD8+T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005 115:739 746. (Pubitemid 40322250)
89. Cooper CL, Davis HL, Angel JB et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005 19:1473 1479.
90. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: A meta-analysis. Clin Infect Dis 2002 35:1368 1375. (Pubitemid 35448965)
91. Kataoka K, McGhee JR, Kobayashi R et al. Nasal Flt3 ligand cDNA elicits CD11c+CD8+dendritic cells for enhanced mucosal immunity. J Immunol 2004 172:3612 3619.
92. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995 374:546 549.
93. Clambey ET, White J, Kappler JW et al. Identification of two major types of age-associated CD8 clonal expansions with highly divergent properties. Proc Natl Acad Sci U S A 2008 105:12997 13002.
94. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006 439:682 687. (Pubitemid 43237609)
95. Velu V, Titanji K, Zhu B et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009 458:206 210.
96. Nikolich-Zugich J. High specificity, not degeneracy, allows T cell alloresponses. Nat Immunol 2007 8:335 337. (Pubitemid 46745406)